“Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records”, J of Skin, vol. 3, no. 2, p. 173, Mar. 2019, doi: 10.25251/skin.3.2.13.